Sector News

Four years after buyout, Pfizer spins Icagen ion channel platform back out

July 2, 2015
Life sciences
Four years ago, Pfizer spent $56 million to bag Icagen and add its ion channel R&D platform and pipeline in North Carolina with its pain drug development arm in the U.K. But yesterday the pharma giant spun the platform back out to a small contract research group in Cambridge, MA, called XRPro Sciences, which will now combine its operations into an expanded research services operation that will cater to the biopharma industry.
 
XRPro CEO Richie Cunningham said that the deal includes a multi-year collaboration with the pharma giant, which gave up the platform for pennies on the dollar.
 
According to an 8-K filed this morning, XRPro is providing a $500,000 upfront, to be paid in installments through early 2016. Another $10.5 million in earn-outs is also up for grabs based on their financial performance.
 
The newly expanded company, which will operate as Icagen, will integrate ion channel and transporter drug tech that CSO Douglas Krafte and his team of 18 have been working on for years. Their work has covered a variety of fields, including cardiac arrhythmias, sickle cell anemia, asthma, epilepsy and pain. XRPro’s 10-person team, meanwhile, has been hawking its expertise in x-ray fluorescence with a variety of customers. The NIH provided a $3 million contract to develop strontium-selective therapies.
 
What did Pfizer get for its $56 million? Krafte points to one pain drug, PF-05089771–a small-molecule Nav1.7 therapy in the clinic–that came off the platform. Pfizer recently combined its pain and neuroscience pipelines into one division and launched a partnership with Eli Lilly to take a second shot at a Phase III for tanezumab. The pharma giant completed a huge reorganization several years ago but continues to trim and rearrange its R&D operations as it sees fit.
 
Biotech companies as well as “large pharmas are looking for efficiencies,” say Cunningham, and the new Icagen plans to provide that for both small molecule development–Icagen’s original area of expertise–along with new work related to biologics.
 
XRPro has been angling to start trading shares over the counter and files regular financial reports with the SEC.
 
According to Cunningham, XRPro Chairman Tim Tyson played a key role in landing the Icagen deal. The former CEO of Valeant–where Cunningham worked–went on to run the R&D services outfit Aptuit from 2008 to 2012 and helped make contact with execs at Pfizer.
 
By John Carroll
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach